News | Page 3 of 10 | 53Biologics

September 3, 2025 Patricia De La Madrid Comments: 0

From Plasmid DNA to Viral Vectors: The Backbone of Gene Therapy

Plasmid DNA (pDNA) has become the essential starting material in modern gene therapy. Without it, producing reliable viral vectors would not be possible. As the field of gene therapy expands, ensuring that pDNA is manufactured at the right scale, purity, and regulatory standard is becoming one of the defining challenges for biotech companies. At 53Biologics, we see plasmid DNA as much more than a raw material: it is the backbone of the entire gene therapy ecosystem. Understanding its role, the c...

August 18, 2025 Patricia De La Madrid Comments: 0

Is the Biopharma World Ready for Artificial Intelligence?

Artificial intelligence (AI) has already become part of everyday life, and it is beginning to reshape the biopharma industry. Its potential is undeniable: accelerating drug discovery, optimizing manufacturing, and bringing therapies to patients faster. Yet readiness remains low—only 14% of large biopharma companies and 3% of smaller ones are prepared to adopt AI, according to Benchling. Artificial Intelligence Roadblocks in Pharma For big pharma, the challenge is complexity. Years of using mul...

August 1, 2025 Patricia De La Madrid Comments: 0

Why Some Biologics Manufacturing Processes Fail to Scale: Challenges and Solutions from 53Biologics

Scaling up biologics manufacturing from lab-scale to GMP production is a critical step that often presents unexpected challenges. While early-stage processes may work efficiently on a small scale, not all bioprocesses translate smoothly to larger volumes or industrial environments. Understanding these obstacles is key for successful technology transfer and commercialization. Common Challenges in Scaling Biologics Manufacturing 1. Biological Complexity and Variability Biologics such as recombinan...

July 22, 2025 Patricia De La Madrid Comments: 0

How GMP Biologics Manufacturing Is Evolving: What 53Biologics Is Doing Differently in 2025

The biopharmaceutical industry is rapidly advancing, with GMP biologics manufacturing at the heart of this transformation. With rising demand for scalable biologics, CDMOs like 53Biologics must continuously adapt to client and regulatory expectations. In 2025, 53Biologics stands out by pairing robust GMP manufacturing with agile, tailored solutions for microbial and mammalian biologics production. Meeting the Rising Demand for Microbial Biologics Microbial expression systems such as E. coli and...

July 8, 2025 Patricia De La Madrid Comments: 0

Choosing the Right Cell Line Strategy: Licensed vs. Unlicensed Cell Lines in Biologics Development

Selecting the optimal cell line is a critical early decision in the development of any biologic drug. It can impact everything from expression yields and product quality to regulatory timelines and commercial strategy. One key consideration for many developers is whether to use a licensed or unlicensed cell line, and the right answer depends on the specific goals, timeline, and product profile. At 53Biologics, we do not offer proprietary strains or cell lines. Instead, we prioritize flexibility....

June 26, 2025 Patricia De La Madrid Comments: 0

Tips for a Successful Process Transfer to a CDMO

Transferring a biopharmaceutical process to a CDMO is a critical milestone in the life cycle of any biologic. Whether you are moving from R&D to GMP manufacturing or scaling up for clinical supply, a well-executed tech transfer can make the difference between smooth project advancement and costly delays. At 53Biologics, we specialize in decoding biologics production, from amino acid sequence to GMP batches. Here are some essential tips to ensure a seamless process transfer and how we can hel...

June 10, 2025 Patricia De La Madrid Comments: 0

53Biologics is heading to BIO International Convention 2025

We are excited to share that Francisco Reyes Sosa will be representing 53Biologics at the BIO International Convention in Boston, USA, this June. BIO is one of the most important gatherings in the biopharmaceutical industry, bringing together thousands of innovators, partners, and experts from across the globe to accelerate the future of biotechnology. At 53Biologics, we specialized in decoding biologics production, from DNA to proteins. As a flexible and experienced CDMO, we specialize in t...

May 21, 2025 Patricia De La Madrid Comments: 0

The Strategic Value of a CDMO in the Pharmaceutical Industry

In an increasingly competitive and regulated biopharmaceutical landscape, the role of a Contract Development and Manufacturing Organization (CDMO) has become a key pillar in accelerating innovation and ensuring the quality of biologics development. But what exactly is the value that a CDMO brings to the industry? And why is its role becoming more strategic? The Growing Complexity of Biopharmaceutical Development The development of biologics is far more complex than traditional pharmaceuticals. B...

May 6, 2025 Patricia De La Madrid Comments: 0

Large-Scale Protein Manufacturing Key Considerations

Scaling up protein manufacturing is a complex and critical step in the biopharmaceutical industry. Unlike small-scale production, large-scale manufacturing presents unique challenges related to maintaining product consistency, optimizing yields, and ensuring compliance with stringent GMP regulations. In this article, we explore the essential factors for successful large-scale protein manufacturing, emphasizing process robustness, efficiency, and regulatory alignment. 1. Process Development and S...

April 30, 2025 Patricia De La Madrid Comments: 0

Applications of pDNA in Biotechnology and Medicine

Plasmid DNA (pDNA) plays a crucial role in modern biotechnology and biopharmaceuticals. From gene therapy to vaccine development, pDNA is a fundamental component driving advancements in medicine. Ensuring high-quality pDNA manufacturing is critical for achieving consistent and reliable results across various applications. 1. Gene Therapy One of the most significant applications of plasmid DNA is in gene therapy, where it serves as a vehicle to introduce therapeutic genes into patient cells. Gene...